Advanced Research and Diagnostic Laboratory (ARDL)

A central biochemistry laboratory

The Advanced Research and Diagnostic Laboratory (ARDL) provides the latest technology and clinical laboratory testing services to researchers and other customers via a 16,000-square-foot customized facility. 

Constructed in 2013, the ARDL facility is recognized worldwide as a front-runner in innovative design and operational excellence.

High-Volume Immunoassay Testing Platforms

High-Volume Immunoassay Testing Platforms

  • Specimen collection / processing
  • Specimen testing and analysis
  • Quality control / assurance
  • Specimen storage

Mass Spectrometer Center

MS Center

  • Sample analysis
  • Quantitative proteomics
  • Assay development
  • Assay validation



  • Long-term sample storage
  • Cell cryopreservation
  • DNA sample storage
  • Power back-up protection


ARDL is fully accredited as a highly complex laboratory by the Clinical Laboratory Improvement Act (CLIA), the College of American Pathologists (CAP), and the New York State Department of Health.  High standards such as these are considered a starting point for ARDL, and a basis for a level of quality unsurpassed in the industry.


ARDL news

MINNEAPOLIS, MN- Oct. 8, 2020 - The University of Minnesota Medical School’s Department of Laboratory Medicine and Pathology has been selected to participate in a new national network dedicated to serological, or antibody, sciences as one of four Capacity Building Centers in the country. As part of the Serological Sciences Network (SeroNet), the team received a five-year, $6.7 million grant to support their part of the network's research effort.

SeroNet is a major component of the National Cancer Institute’s (NCI) response to the pandemic and is included in an emergency Congressional appropriation of $306 million to the Institute “to develop, validate, improve and implement serological testing and associated technologies.”

“We are looking forward to joining this important effort to help expand our knowledge surrounding immunity to COVID-19,” said Amy Karger, MD, PhD, an associate professor in the department and the principal investigator for the initiative, who leads the University’s Advanced Research and Diagnostic Laboratory, where a majority of the state’s serology work takes place. “We were positioned for this opportunity thanks to the efforts of Dr. Marc Jenkins and his lab in developing an antibody test that has proven to be so reliable.”

Full story here.